Montero, Joan
Gstalder, Cécile
Kim, Daniel J.
Sadowicz, Dorota http://orcid.org/0000-0002-9567-3982
Miles, Wayne
Manos, Michael
Cidado, Justin R.
Paul Secrist, J.
Tron, Adriana E.
Flaherty, Keith http://orcid.org/0000-0002-3402-0478
Stephen Hodi, F.
Yoon, Charles H.
Letai, Anthony http://orcid.org/0000-0002-1993-9013
Fisher, David E.
Haq, Rizwan http://orcid.org/0000-0002-1290-9276
Funding for this research was provided by:
Melanoma Research Alliance
O’Connor-MacGregor Fund for Melanoma Research
Article History
Received: 19 December 2018
Accepted: 6 August 2019
First Online: 14 November 2019
Competing interests
: K.F. is a member of the board of directors at Loxo Oncology, Clovis Oncology, Strata Oncology, Vivid Biosciences; the corporate advisory board of X4 Pharmaceuticals, PIC Therapeutics; the scientific advisory board of Sanofi, Amgen, Asana, Adaptimmune, Fount, Aeglea, Array BioPharma, Shattuck Labs, Arch Oncology, Tolero, Apricity, Oncoceutics, Fog Pharma, Tvardi; and consultant for Novartis, Genentech, Bristol-Myers Squibb, Merck, Takeda, Verastem, Checkmate, Boston Biomedical. F.S.H. is a consultant for Bristol-Myers Squibb, Merck, EMD Serono, Novartis, Celldex, Amgen, Genetech, Incyte, Bayer, Aduro, Partners Therapeutics, Sanofi, Pfizer, Pionyr; member of scientific advisory board of Apricity; member of the advisory board of Pionyr, 7 Hills Pharma, Verastem. R.H. has received research grants from Bristol-Myers-Squibb and Novartis. J.R.C., A.E.T., and J.P.S. are employees of Astra-Zeneca. C.Y. is a consultant to Merck. J.M. is a consultant for Vivid Biosciences and Oncoheroes Biosciences. D.E.F. has a financial interest in Soltego, Inc., a company developing SIK inhibitors for topical skin darkening treatments that might be used for a broad set of human applications. These interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. The remaining authors declare no competing interests.